On this page
Back to topAardvark Therapeutics AARD
Aardvark Therapeutics listed on Nasdaq on 13 Feb 2025 and is not in the S&P 500. It is worth $21.9 million. Its board has 5 directors, 4 of them independent. 2 other officers are on file.
- Chair and CEO
- Tien-Li Lee
- Listed
- 13 Feb 2025 on Nasdaq
- Headquarters
- San Diego, CA
- Market cap
- $22M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Aardvark Therapeutics' market cap since February 2025
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $30M |
| 26 Dec 2025 | $300M |
Download Aardvark Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 14 Feb 2025.
Board and leadership
Board and officers
Board from the proxy filed 10 Jul 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (5) | |||||
| Tien-Li LeeChair; Chief Executive OfficerNot independent 路 since 2017 | |||||
| Roy D. BaynesDirectorIndependent 路 since 2024 路 Compensation, Nominating and Corporate GovernanceExecutive Vice President and Chief Medical Officer, Eikon Therapeutics, Inc.Other boards: Eikon Therapeutics, Natera, Travere Therapeutics and Nurix Therapeutics | |||||
| Jeffrey ChiLead Independent DirectorIndependent 路 since 2019 路 Audit, Compensation (chair), Nominating and Corporate GovernanceSenior Consultant, Vickers Venture PartnersOther boards: Jing-jin Electric Technologies Co., Ltd. | |||||
| Susan E. GrafDirectorIndependent 路 since 2024 路 Audit (chair), CompensationSenior Advisor and Entrepreneur in Residence, Locust Walk Partners, LLCOther boards: CG Oncology | |||||
| Victor Edward Tong Jr.DirectorIndependent 路 since 2024 路 Audit, Nominating and Corporate Governance (chair)Managing Director, Decheng CapitalOther boards: CG Oncology | |||||
| Officers (2) | |||||
| Manasi JaimanChief Medical OfficerLast filed 11 Feb 2026 | |||||
| Nelson SunChief Financial & Operating OfficerLast filed 11 Sep 2026 | |||||
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $394,930 of stock in 2 sales and bought $144,630 in 2 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 11 Sep 2026Sale | Nelson SunChief Financial & Operating Officer | $321K |
| 10 Sep 2026Sale | Nelson SunChief Financial & Operating Officer | $74K |
| 11 Dec 2025Buy | Tien-Li LeeChief Executive Officer | $101K |
| 11 Dec 2025Buy | Nelson SunChief Financial & Operating Officer | $43K |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 departure and 2 appointments of directors and officers and 1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Aardvark Therapeutics' insider sales.
Events, newest first
- 6 Oct 2026 David (Zhongwei) Zhang appointedClass II director, effective 7 Oct 2026
- 11 Sep 2026 Nelson Sun sold $321KChief Financial & Operating Officer
- 9 Feb 2026 Bryan Jones leftChief Operating Officer
- 9 Feb 2026 Nelson Sun appointedChief Operating Officer
Not on file: no 13F holdings reported, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.